Home
About Us
About YolTech
Leadership
Advisory Board
Investors
Science
Genome Editing Platform
LNP Delivery Platform
Pipeline
Pipeline
Metabolic Disease
Genetic Disease
Infectious Disease
Disease
Familial Hypercholesterolemia (FH)
Hereditary Transthyretin Amyloidosis (ATTR)
Atherosclerotic Cardiovascular Disease (ASCVD)
Primary Hyperoxaluria (PH1)
Hereditary Angioedema (HAE)
Hepatitis B
News
Press Release
YolTech Secures Patent for Innovative DNA Editing System
First Patient Dosed in Clinical Trial of YOLT-101 for the Treatment of FH
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
YolTech Gains Patent for Advanced Base Editing Technology
YolTech Announces Appointment of Tony W.Ho as Scientific Advisor
First Patient Dosed in Clinical Trial of YOLT-201 for ATTR-CM
YolTech’s Founder Interviewed by UCB China Voice Journal
YolTech Announces NMPA Acceptance of IND Application for YOLT-201 to Treat hATTR
YolTech Secured $15 Million in Series A+ Financing
Media Release
CDE Clears IND Application for Therapeutic Candidate Targeting ATTR
YolTech Therapeutics to Showcase Breakthroughs in in vivo Gene Editing at TIDES Asia 2024
Landmark Clinical Approval for YOLT-201 Obtained by the NMPA
Investing in the Next Frontier of Healthcare: Navigating Opportunities in
In Vivo
Gene Editing Technologies
YolTech Therapeutics to Present and Unveil Major Progress at Biotech Showcase 2024
First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM
Publication
Career
Corporate Culture
Job Opportunites
Contact Us
contact